Why is ipamorelin preferred over GHRP-2 or GHRP-6?

Ipamorelin is selective for the GH secretion signal and does not produce the cortisol, ACTH, or prolactin co-stimulation seen with GHRP-2 and GHRP-6. Raun et al. 1998 (PMID 9849822) demonstrated this selectivity: at GH-stimulating doses in rats, ipamorelin produced GH release without meaningful HPA axis co-activation, while GHRP-2 and GHRP-6 produced dose-dependent cortisol/ACTH responses. This makes ipamorelin the canonical selective ghrelin mimetic in research protocols pairing a GHRH analogue with a ghrelin-mimetic secretagogue.

What does the CJC-1295 + ipamorelin mechanism actually prove about muscle growth?

The evidence proves these compounds elevate GH and IGF-1 in humans (Teichman 2006 PMID 16352683: GH 2–10×, IGF-1 1.5–3× after a single CJC-1295 dose). GH/IGF-1 elevation activates PI3K-Akt-mTOR signalling, the anabolic pathway involved in protein synthesis. What the evidence does NOT prove: no published human RCT of CJC-1295, ipamorelin, or their combination has measured lean body mass, muscle cross-sectional area, or strength as primary endpoints. IGF-1 elevation is not equivalent to demonstrated muscle growth in humans.

What is DAC and does CJC-1295 without DAC work the same way?

DAC (drug affinity complex) is a maleimide-polyethylene glycol modification that covalently conjugates CJC-1295 to serum albumin upon administration, extending its half-life from ~7 minutes to ~6–8 days. CJC-1295 without DAC (mod GRF 1-29) activates the same GHRH-R receptor but has a half-life of approximately 30 minutes, producing a more acute, pulsatile GH pulse rather than sustained elevation. Both act via the identical GHRH-R → Gs → cAMP → PKA mechanism.

Is CJC-1295 + Ipamorelin FDA-approved?

No. Neither CJC-1295 nor ipamorelin is an FDA-approved drug. As of April 2026, both are on the FDA 503A Category 2 compounding Bulks List — meaning they are designated as unapproved drugs with potential safety risks and have been removed from compounding pharmacy pathways. Titan supplies the CJC-1295 + Ipamorelin blend for research use only.

CJC-1295 + ipamorelin mechanism · GHRH receptor · ghrelin receptor · research use only

How Does CJC-1295 + Ipamorelin Work? The Dual-Receptor GH Mechanism

CJC-1295 and ipamorelin are two structurally and mechanistically distinct compounds that are studied together because they engage the pituitary growth hormone (GH) axis through two entirely different receptor systems. CJC-1295 is a synthetic GHRH analogue that activates growth hormone-releasing hormone receptors (GHRH-R) on anterior pituitary somatotrophs, amplifying GH pulse amplitude and sustaining GH secretion for days. Ipamorelin is a synthetic pentapeptide ghrelin mimetic that activates ghrelin receptors (GHSR-1a) on the same cells, initiating GH pulse onset with a highly selective profile that avoids cortisol, ACTH, and prolactin co-stimulation. When used together in research models, the two compounds engage complementary receptor pathways to produce additive or synergistic GH release that is greater than either compound alone. This page explains each receptor axis with the primary cited data. All information is general educational context about research compounds. Titan Peptide Lab supplies CJC-1295 + Ipamorelin Blend for laboratory and research use only — not for human use, not as a drug or therapeutic product, not as medical advice.

CJC-1295 + Ipamorelin — $119.99 (RUO)CJC-1295 + Ipamorelin dosage reference

What CJC-1295 is and the GHRH-R mechanism

CJC-1295 (with DAC — drug affinity complex) is a 30-amino acid synthetic analogue of growth hormone-releasing hormone (GHRH), the endogenous hypothalamic peptide that drives pulsatile GH secretion. The DAC modification covalently links the peptide to serum albumin via a reactive maleimide group, extending its half-life from ~7 minutes (native GHRH) to approximately 6–8 days. CJC-1295 acts at GHRH receptors (GHRH-R) on anterior pituitary somatotrophs — Gs-coupled GPCRs that activate adenylyl cyclase → cAMP → PKA → GH gene transcription and vesicular exocytosis. Teichman et al. 2006 (JCEM 91:799-805, PMID 16352683) demonstrated that a single dose of CJC-1295 in healthy adults produced a 2–10-fold elevation in mean GH concentration sustained for more than 6 days, with IGF-1 rising 1.5–3-fold at 14 days. Multiple-dose protocols produced IGF-1 elevations of approximately 2-fold at 28 days. This sustained GH elevation profile is mechanistically explained by the GHRH-R → cAMP cascade remaining continuously engaged due to the long albumin-bound half-life. A related compound, mod GRF 1-29 (sometimes called CJC-1295 without DAC), lacks the albumin conjugation and has a half-life of ~30 minutes — producing a more acute, pulsatile pharmacokinetic profile via the same receptor.

CJC-1295 + Ipamorelin dosage reference →

What ipamorelin is and the GHSR-1a mechanism

Ipamorelin (Aib-His-D-2Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide growth hormone secretagogue (GHS). It is a ghrelin mimetic — it activates the growth hormone secretagogue receptor 1a (GHSR-1a, also called the ghrelin receptor) on pituitary somatotrophs. The GHSR-1a is a Gq/11-coupled GPCR that signals through phospholipase C → IP3/DAG → intracellular calcium release, a pathway that is independent of and complementary to the GHRH-R cAMP cascade. Raun et al. 1998 (Eur J Endocrinol 139:552-561, PMID 9849822) established that ipamorelin is a highly selective GH secretagogue in rats: unlike GHRP-2 and GHRP-6 (earlier GHS compounds), ipamorelin does not produce clinically relevant cortisol, ACTH, or prolactin co-stimulation at GH-stimulating doses. This selectivity is the defining characteristic that distinguishes ipamorelin from other ghrelin-mimetic GHS peptides — it isolates the GH secretion signal from the broader HPA axis activation associated with earlier compounds.

Peptides for muscle growth research hub →

The synergy: two receptors, two signalling pathways

The mechanistic rationale for combining CJC-1295 and ipamorelin is that they activate the same target cells (anterior pituitary somatotrophs) via two distinct intracellular signalling axes: CJC-1295 → GHRH-R → Gs → cAMP → PKA; ipamorelin → GHSR-1a → Gq/11 → PLC → Ca2+. These two pathways converge on GH vesicle exocytosis through different upstream routes, producing additive or synergistic GH release. Hataya et al. 2001 (JCEM 86:4552-4555, PMID 11549707) demonstrated in human research subjects that co-administration of ghrelin and GHRH produced greater GH release than either compound alone — establishing the synergistic potential of simultaneous GHSR-1a and GHRH-R activation. The combination effectively reproduces two endogenous signals (hypothalamic GHRH + gastric ghrelin) that are normally co-active during the peak physiological GH pulse. HONEST CAVEAT: no published human RCT has studied the specific CJC-1295 + ipamorelin combination as a single co-administered regimen with body composition endpoints — the existing evidence is Teichman 2006 for CJC-1295 (GH/IGF-1 PK endpoints only) and Raun 1998 for ipamorelin selectivity (animal data). The two-receptor synergy is pharmacologically documented but clinically the combination has not been studied in registered human trials measuring lean mass, recovery, or other functional outcomes.

Does CJC-1295 build muscle? Evidence review →

Downstream of GH: the IGF-1 → PI3K-Akt-mTOR axis

Both receptor pathways ultimately drive anterior pituitary GH secretion. GH then enters systemic circulation and acts on the liver as the primary target, stimulating IGF-1 synthesis and secretion. IGF-1 is the downstream mediator of most GH's studied anabolic and tissue-remodelling effects: it activates IGF-1R (insulin-like growth factor receptor 1) → PI3K → Akt → mTOR signalling, the canonical anabolic pathway involved in protein synthesis and cell growth. Velloso (Br J Pharmacol 2008;154:557-568) characterised the IGF-1→PI3K-AKT-mTOR axis in skeletal muscle. In Teichman 2006, IGF-1 elevation from CJC-1295 began at day 7 and peaked around day 14–21 after a single dose, consistent with the downstream lag between GH secretion and hepatic IGF-1 synthesis. HONEST CAVEAT: elevation of GH and IGF-1 is the documented pharmacological effect; muscle protein synthesis and lean mass accrual represent extrapolation from the IGF-1 pathway and have not been directly measured in CJC-1295 or ipamorelin human RCTs.

CJC-1295 + Ipamorelin stack overview →

Why ipamorelin's selectivity matters: no cortisol/ACTH co-stimulation

Earlier GHS compounds such as GHRP-2 and GHRP-6 stimulate GH but also produce dose-dependent cortisol and ACTH elevation — an HPA axis activation considered undesirable in most research contexts. Ipamorelin's structural selectivity for GHSR-1a avoids this HPA co-stimulation. Raun et al. 1998 showed that ipamorelin-stimulated GH release in rats was not accompanied by meaningful cortisol, ACTH, or prolactin responses even at supra-physiological GHS doses. The mechanistic basis for this selectivity is not fully elucidated, but ipamorelin's pentapeptide structure (Aib-His-D-2Nal-D-Phe-Lys-NH2) appears to achieve high affinity at GHSR-1a without activating the downstream G-protein coupling pathways that mediate ACTH/cortisol release in corticotrophs. This selective profile is why ipamorelin — rather than GHRP-2 or GHRP-6 — is the canonical ghrelin-mimetic component in the CJC-1295+ipamorelin research pairing.

CJC-1295 + Ipamorelin safety data →

What the mechanism data doesn't establish

The mechanistic evidence for CJC-1295 and ipamorelin individually is well-documented — Teichman 2006 is a registered human trial with clear GH/IGF-1 PK data; Raun 1998 establishes ipamorelin's selectivity in rats. What the evidence does NOT establish: (1) no human RCT of the combined CJC-1295+ipamorelin blend has been published with body composition, recovery, or performance endpoints; (2) GH and IGF-1 elevation does not automatically equate to lean mass gain — White 2009 (capromorelin) and Nass 2008 (MK-677) showed only modest lean mass changes despite sustained IGF-1 elevation; (3) both CJC-1295 and ipamorelin are on the FDA 503A Category 2 compounding list (April 2026), reflecting their status as unapproved drugs; (4) the specific CJC-1295+ipamorelin blend Titan supplies is for research use only and is not approved for any therapeutic use.

CJC-1295 + Ipamorelin full research guide →

Dual-receptor mechanism — sourced and plain

CJC-1295 + ipamorelin: two receptor pathways converging on pituitary GH release.

Each row covers one mechanistic component or key cited fact. The two-receptor model is the mechanistic basis for the combination's studied synergistic GH profile.

CJC-1295: GHRH-R → cAMP → PKA: CJC-1295 binds GHRH-R on anterior pituitary somatotrophs (Gs-coupled GPCR) → adenylyl cyclase → ↑cAMP → PKA activation → GH gene transcription + exocytosis. Half-life extended to ~6-8 days via DAC albumin conjugation. Teichman 2006 PMID 16352683: 2–10× GH elevation sustained >6 days; IGF-1 ↑1.5–3× at day 14.
Ipamorelin: GHSR-1a → Gq/11 → Ca2+: Ipamorelin activates GHSR-1a (ghrelin receptor) on somatotrophs via Gq/11 → PLC → IP3/DAG → intracellular Ca2+ release. Pathway independent of GHRH-R cAMP axis. Raun 1998 PMID 9849822: selective GH release WITHOUT cortisol/ACTH/prolactin co-stimulation (contrast GHRP-2/GHRP-6).
Two-receptor synergy: CJC-1295 (GHRH-R/cAMP) + ipamorelin (GHSR-1a/Ca2+) activate complementary intracellular pathways in the same somatotrophs. Hataya 2001 PMID 11549707 (ghrelin+GHRH): greater GH response than either alone in humans, establishing the synergy principle. No human RCT of the specific CJC-1295+ipamorelin co-administration has been published.
Downstream: GH → IGF-1 → PI3K-Akt-mTOR: Both pathways → pituitary GH secretion → hepatic IGF-1 synthesis (7–14 day lag). IGF-1 → IGF-1R → PI3K-AKT-mTOR = canonical anabolic pathway. GH/IGF-1 elevation is the documented pharmacological endpoint; direct lean mass accrual has not been measured in CJC-1295 or ipamorelin human RCTs.
HPA axis sparing (ipamorelin): Ipamorelin's selectivity at GHSR-1a avoids cortisol/ACTH co-stimulation. Structural basis not fully elucidated but confirmed in Raun 1998 rat models at supra-GHS doses. Explains why ipamorelin rather than GHRP-2/6 is the canonical GHS partner in CJC-1295 research stacks.
FDA Category 2 status (April 2026): Both CJC-1295 and ipamorelin are on the FDA 503A Category 2 compounding Bulks List as of April 2026 — they are classified as drugs presenting 'potential safety risks' and have been removed from the compounding pathway. They are not FDA-approved drugs and are supplied by Titan for research use only.

Questions researchers ask

Before you order.

How does CJC-1295 ipamorelin work?: CJC-1295 and ipamorelin work through two distinct receptor systems on the same anterior pituitary cells (somatotrophs). CJC-1295 activates GHRH receptors (Gs-coupled → cAMP → PKA → GH secretion), while ipamorelin activates ghrelin receptors (GHSR-1a, Gq/11 → Ca2+ → GH secretion). These complementary pathways activate GH release through additive intracellular signals — the same principle as the documented synergy between GHRH + ghrelin in humans (Hataya et al. 2001, PMID 11549707). The result is greater GH release than either compound alone.
Why is ipamorelin preferred over GHRP-2 or GHRP-6?: Ipamorelin is selective for the GH secretion signal and does not produce the cortisol, ACTH, or prolactin co-stimulation seen with GHRP-2 and GHRP-6. Raun et al. 1998 (PMID 9849822) demonstrated this selectivity: at GH-stimulating doses in rats, ipamorelin produced GH release without meaningful HPA axis co-activation, while GHRP-2 and GHRP-6 produced dose-dependent cortisol/ACTH responses. This makes ipamorelin the canonical selective ghrelin mimetic in research protocols pairing a GHRH analogue with a ghrelin-mimetic secretagogue.
What does the CJC-1295 + ipamorelin mechanism actually prove about muscle growth?: The evidence proves these compounds elevate GH and IGF-1 in humans (Teichman 2006 PMID 16352683: GH 2–10×, IGF-1 1.5–3× after a single CJC-1295 dose). GH/IGF-1 elevation activates PI3K-Akt-mTOR signalling, the anabolic pathway involved in protein synthesis. What the evidence does NOT prove: no published human RCT of CJC-1295, ipamorelin, or their combination has measured lean body mass, muscle cross-sectional area, or strength as primary endpoints. IGF-1 elevation is not equivalent to demonstrated muscle growth in humans.
What is DAC and does CJC-1295 without DAC work the same way?: DAC (drug affinity complex) is a maleimide-polyethylene glycol modification that covalently conjugates CJC-1295 to serum albumin upon administration, extending its half-life from ~7 minutes to ~6–8 days. CJC-1295 without DAC (mod GRF 1-29) activates the same GHRH-R receptor but has a half-life of approximately 30 minutes, producing a more acute, pulsatile GH pulse rather than sustained elevation. Both act via the identical GHRH-R → Gs → cAMP → PKA mechanism.
Is CJC-1295 + Ipamorelin FDA-approved?: No. Neither CJC-1295 nor ipamorelin is an FDA-approved drug. As of April 2026, both are on the FDA 503A Category 2 compounding Bulks List — meaning they are designated as unapproved drugs with potential safety risks and have been removed from compounding pharmacy pathways. Titan supplies the CJC-1295 + Ipamorelin blend for research use only.